Recombinant bacterial expression and purification of human fragile X mental retardation protein isoform 1

Area of Science:

• Molecular Biology
• Neuroscience
• Genetics

Background:

• Fragile X syndrome results from the loss of fragile X mental retardation protein (FMRP).
• FMRP, containing RNA binding domains, regulates specific messenger RNA translation.
• Previous attempts at recombinant FMRP expression in bacteria, eukaryotes, and in vitro systems yielded limited success and potential posttranslational modifications.

Purpose of the Study:

• To establish optimal conditions for high-yield recombinant FMRP expression, purification, and storage using Escherichia coli.
• To obtain FMRP devoid of posttranslational modifications like phosphorylation and arginine methylation for studying their direct effects.
• To confirm the retained activity of purified FMRP throughout the production and storage process.

Main Methods:

• Recombinant expression of FMRP in Escherichia coli.
• Protein purification techniques.
• Fluorescence spectroscopy to assay FMRP's arginine-glycine-glycine box binding activity to semaphorin 3F mRNA.

Main Results:

• Successfully established conditions for high-yield recombinant FMRP expression and purification in E. coli.
• The E. coli expression system produced FMRP lacking phosphorylation and arginine methylation.
• Fluorescence spectroscopy confirmed that the purified FMRP retained its RNA binding activity.

Conclusions:

• Recombinant expression of FMRP in E. coli provides a viable method for obtaining large quantities of pure, unmodified protein.
• This purified FMRP is suitable for biochemical and biophysical studies, including investigations into the effects of posttranslational modifications.
• The established protocol ensures FMRP activity is maintained, facilitating further research into fragile X syndrome mechanisms.